Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.
Haiyan ZhangZhiping FanFen HuangLijie HanYajing XuNa XuLan DengShunqing WangDongjun LinXiaodan LuoQing ZhangXiaodan LiuXudong LiXinquan LiangShuangfeng XieHong QuSijian YuHong-Sheng ZhouPengcheng ShiLi XuanRen LinHui LiuHua JinJing SunQi-Fa LiuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The BuCy regimen has noninferior efficiency and safety as TBI-Cy (4.5 Gy × 2) for patients with adult standard-risk B cell-ALL in CR1 undergoing HLA-matched allo-HSCT.
Keyphrases
- phase iii
- double blind
- open label
- high dose
- clinical trial
- low dose
- liver failure
- phase ii
- traumatic brain injury
- placebo controlled
- acute myeloid leukemia
- respiratory failure
- bone marrow
- drug induced
- aortic dissection
- allogeneic hematopoietic stem cell transplantation
- severe traumatic brain injury
- cross sectional
- randomized controlled trial
- radiation induced
- hepatitis b virus
- mild traumatic brain injury
- hematopoietic stem cell
- intensive care unit
- childhood cancer
- young adults
- mechanical ventilation